PURPOSE OF REVIEW: To critically discuss the attributable mortality of ventilator-associated pneumonia (VAP) and potential sources of variation. RECENT FINDINGS: The review will cover the available estimates (0-50%). It will also explore the source of variation because of definition of VAP (being lower if inaccurate), case-mix issues (being lower for trauma patients), the severity of underlying illnesses (being maximal when the severity of underlying illness is intermediate), and on the characteristics and the severity of the VAP episode. Another important source of variation is the use of poorly appropriate statistical models (estimates biased by lead time bias and competing events). New extensions of survival models which take into account the time dependence of VAP occurrence and competing risks allow less biased estimation as compared with traditional models. SUMMARY: Attributable mortality of VAP is about 6%. Accurate diagnostic methods are key to properly estimating it. Traditional statistical models should no longer be used to estimate it. Prevention efforts targeted on patients with intermediate severity may result in the most important outcome benefits.
PURPOSE OF REVIEW: To critically discuss the attributable mortality of ventilator-associated pneumonia (VAP) and potential sources of variation. RECENT FINDINGS: The review will cover the available estimates (0-50%). It will also explore the source of variation because of definition of VAP (being lower if inaccurate), case-mix issues (being lower for traumapatients), the severity of underlying illnesses (being maximal when the severity of underlying illness is intermediate), and on the characteristics and the severity of the VAP episode. Another important source of variation is the use of poorly appropriate statistical models (estimates biased by lead time bias and competing events). New extensions of survival models which take into account the time dependence of VAP occurrence and competing risks allow less biased estimation as compared with traditional models. SUMMARY: Attributable mortality of VAP is about 6%. Accurate diagnostic methods are key to properly estimating it. Traditional statistical models should no longer be used to estimate it. Prevention efforts targeted on patients with intermediate severity may result in the most important outcome benefits.
Authors: N Cobos-Trigueros; M Rinaudo; M Solé; P Castro; J Pumarol; C Hernández; S Fernández; J M Nicolás; J Mallolas; J Vila; L Morata; J M Gatell; A Soriano; J Mensa; J A Martínez Journal: Eur J Clin Microbiol Infect Dis Date: 2013-10-23 Impact factor: 3.267
Authors: Yanyan Qu; Tolani Olonisakin; William Bain; Jill Zupetic; Rebecca Brown; Mei Hulver; Zeyu Xiong; Jesus Tejero; Robert Mq Shanks; Jennifer M Bomberger; Vaughn S Cooper; Michael E Zegans; Hyunryul Ryu; Jongyoon Han; Joseph Pilewski; Anuradha Ray; Zhenyu Cheng; Prabir Ray; Janet S Lee Journal: JCI Insight Date: 2018-02-08
Authors: Tjallie van der Kooi; Alain Lepape; Pascal Astagneau; Carl Suetens; Mioara Alina Nicolaie; Sabine de Greeff; Ilma Lozoraitiene; Jacek Czepiel; Márta Patyi; Diamantis Plachouras Journal: Euro Surveill Date: 2021-06